These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


296 related items for PubMed ID: 19434583

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group.
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 9. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA, Rivera VM.
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [Abstract] [Full Text] [Related]

  • 10. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 11. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
    Funct Neurol; 2006 May; 21(3):145-9. PubMed ID: 17049133
    [Abstract] [Full Text] [Related]

  • 12. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group.
    J Neurol Sci; 2005 Dec 15; 239(1):67-74. PubMed ID: 16169561
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 14. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L.
    J Neurol; 2003 Dec 15; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 15; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 18. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun 15; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 19. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis.
    Then Bergh F, Kümpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C.
    Clin Endocrinol (Oxf); 2007 Feb 15; 66(2):295-303. PubMed ID: 17224002
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
    Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, Rebif New Formulation Study Group.
    Mult Scler; 2009 Feb 15; 15(2):219-28. PubMed ID: 18755819
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.